Multiple Sclerosis: Greater New England Chapter Stanley F. Waterman Research Update and Annual Meeting of Members

Current Treatments
BETASERON® (interferon beta-1b) is indicated for the treatment of relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations. Patients with multiple sclerosis in whom efficacy has been demonstrated include patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis

AVONEX® (Interferon beta-1a) is a 166 amino acid glycoprotein with a predicted molecular weight of approximately 22,500 daltons. It is produced by recombinant DNA technology using genetically engineered Chinese Hamster Ovary cells into which the human interferon beta gene has been introduced. The amino acid sequence of AVONEX® is identical to that of natural human interferon beta.

COPAXONE is the brand name for glatiramer acetate (formerly known as copolymer-1). Glatiramer acetate, the active ingredient of COPAXONE, consists of the acetate salts of synthetic polypeptides, containing four naturally occurring amino acids: L-glutamic acid, L-alanine, L-tyrosine, and L-lysine with an average molar fraction of 0.141, 0.427, 0.095, and 0.338, respectively. The average molecular weight of glatiramer acetate is 5,000 – 9,000 daltons. Glatiramer acetate is identified by specific antibodies.

Rebif® (interferon beta-1a) is a purified 166 amino acid glycoprotein with a molecular weight of approximately 22,500 daltons. It is produced by recombinant DNA technology using genetically engineered Chinese Hamster Ovary cells into which the human interferon beta gene has been introduced. The amino acid sequence of Rebif® is identical to that of natural fibroblast derived human interferon beta. Natural interferon beta and interferon beta-1a (Rebif®) are glycosylated with each containing a single N-linked complex carbohydrate moiety.

Tysabri is a monoclonal antibody that affects the actions of the body's immune system. Monoclonal antibodies are made to target and destroy only certain cells in the body. This may help to protect healthy cells from damage. Tysabri is used to treat relapsing forms of multiple sclerosis.

Gilenya™ is a new class of medication called a phingosine 1-phosphate receptormodulator, which is thought to act by retaining certain white blood cells (lympohcytes) in the lymph nodes, thereby preventing those cells from crossing the blood-brain barrier into the central nervous system (CNS). Preventing the entry of these cells into the CNS reduces inflammatory damage to nerve cells.

Early Symptoms
The most common early symptoms of MS include:
* Tingling * Numbness
* Loss of balance
* Weakness in one or more limbs
* Blurred or double vision

Less common symptoms of MS may include
* Slurred speech
* Sudden onset of paralysis
* Lack of coordination
* Cognitive difficulties

Listed above, the early symptoms. I tend to be a poster child for these. The symptoms that occur later on are too numerous just to list. There will be a link included that will get you to a site where these symptoms are listed and explained. Keep in mind that someone may have some of these or many of these, there is no way to tell.

Multiple sclerosis statistics show that approximately 250,000 to 350,000 people in the United States have been diagnosed with this disease. The life expectancy for people with multiple sclerosis is nearly the same as for those without MS. Because of this, multiple sclerosis statistics place the annual cost of MS in the United States in the billions of dollars. MS is five times more prevalent in temperate climates -- such as those found in the northern United States, Canada, and Europe -- than in tropical regions. Furthermore, the age of 15 seems to be significant in terms of risk for developing the disease. Some studies indicate that a person moving from a high-risk (temperate) to a low-risk (tropical) area before the age of 15 tends to adopt the risk (in this case, low) of the new area and vice versa. Other studies suggest that people moving after age 15 maintain the risk of the area where they grew up.

The National MS Society

Friday, October 15, 2010

Greater New England Chapter Stanley F. Waterman Research Update and Annual Meeting of Members

Saturday, October 23, 2010
11:15 am - 3:00 pm
Lunch is provided

In addition to the Chapter-wide Annual Meeting, each state features a guest speaker, who addresses current and emerging MS research. This year we focus on our collective vision: a world free of MS. Research has never been more promising!

Maine: Nicholas G. LaRocca, PhD V.P., Health Care Delivery and Policy Research National Multiple Sclerosis Society Topic: MS Research You Might Not Know About

Massachusetts: Mark Freedman, MD Dir., Multiple Sclerosis Research Unit, Ottawa Hospital University of Ottawa, Ottawa, Canada Topic: Stem Cell Based Therapies: The Promise and Challenges of Treating MS.

New Hampshire: John Randolph PhD Clinical Neuropsychologist, Private practice, Lebanon, New Hampshire Topic: Cognitive Functioning in MS: An Update on What We Know

Vermont: Lloyd Kasper, MD Medical Director, Multiple Sclerosis Clinic Dartmouth Hitchcock Medical Center Topic: B cells and T cells in MS: In the Garden of Good and Evil

Four states, four locations!

Register now for the location nearest you:
# Hilton Garden Inn, Auburn, Maine
# Best Western Royal Plaza, Marlborough, Massachusetts
# Church Landing, Meredith, New Hampshire
# Killington Grand Resort, Killington, Vermont

Visit http://www.msnewengland.org/ to register for this program online.

Facebook Become a fan of the Greater New England Chapter on Facebook

National Multiple Sclerosis Society
Greater New England Chapter
101A First Avenue, Suite 6
Waltham, MA 02451-1115
tel: 1 800-344-4867
fax: 1 781-890-2089
MSnewengland.org

National MS Society | Legal Notice/Privacy Policy | Email Preferences | Unsubscribe

National Multiple Sclerosis Society | 733 Third Avenue | New York, NY | 10017

Contact us at: http://www.nationalmssociety.org/ or 1-800-344-4867.

No comments:

Subscribe to: Post Comments (Atom)